The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Nr2e3 is a genetic modifier that rescues retinal degeneration and promotes homeostasis in multiple models of retinitis pigmentosa
Open accessAbstract
Recent advances in viral vector engineering, as well as an increased understanding of the cellular and molecular mechanism of retinal diseases, have led to the development of novel gene therapy approaches. Furthermore, ease of accessibility and ocular immune privilege makes the retina an ideal target for gene therapies. In this study, the nuclear hormone receptor gene Nr2e3 was evaluated for efficacy as broad-spectrum therapy to attenuate early to intermediate stages of retinal degeneration in five unique mouse models of retinitis pigmentosa (RP). RP is a group of heterogenic inherited retinal diseases associated with over 150 gene mutations, affecting over 1.5 million individuals worldwide. RP varies in age of onset, severity, and rate of progression. In addition, ~40% of RP patients cannot be genetically diagnosed, confounding the ability to develop personalized RP therapies. Remarkably, Nr2e3 administered therapy resulted in reduced retinal degeneration as observed by increase in photoreceptor cells, improved electroretinogram, and a dramatic molecular reset of key transcription factors and associated gene networks. These therapeutic effects improved retinal homeostasis in diseased tissue. Results of this study provide evidence that Nr2e3 can serve as a broad-spectrum therapy to treat multiple forms of RP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures













Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies have shown that modifier genes, such as nuclear hormone receptors, have the potential to “reset” various networks related to retinal disease phenotypes, such as photoreceptor development, phototransduction, metabolism, cone cell development, inflammation, and cell survival, thus restoring the homeostasis in the retina to a healthy state.47,50–53”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [52]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Modifier gene therapy has the potential to alter the retinal disease state even in the absence of a genetic diagnosis or in the absence of a gene therapy specific to the mutated gene in one of these patients.47,50–53”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yoshida, H., Matsui, T., Yamamoto, A., Okada, T., & Mori, K. (2001) · Cell · doi:10.1016/s0092-8674(01)00611-0 · Cited by 4,039
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“Gene therapy has evolved from concept to clinic for various genetic disorders including hematological [2], immunological [3], ocular [4, 5], neuro-degenerative [6], and metabolic disorders [7].”
BackgroundGene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202 · cited 1×
“The most widely accepted success of adeno-associated virus (AAV) vector-mediated ocular gene replacement is for treatment of Leber ’ s congenital amaurosis 2 (LCA2), a rare retinal disease due to mutations in the RPE65 gene [8, 9].”
BackgroundHamel, C. (2006) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-1-40 · Cited by 962
Bowes, C., Li, T., Danciger, M., Baxter, L. C., Applebury, M. L., & Farber, D. B. (1990) · Nature · doi:10.1038/347677a0 · Cited by 852
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796
The Role of Orphan Nuclear Receptors in the Regulation of Cholesterol Homeostasis
Repa, J. J., & Mangelsdorf, D. J. (2000) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.16.1.459 · Cited by 759
Dalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734
Research works printed but not linked: 3
- Haider NB, Naggert JK, Nishina PM. Excess cone cell proliferation due to lack of a functional NR2E3 causes retinal dysplasia and degeneration in rd7/rd7 mice. Hum Mol Genet. 2001;10:1619–26. · DOI · Paper page
- Webber A, Hodor P, Thut C, Petrukhin K. Dual role of Nr2e3 in photoreceptor development and maintenance. Exp Eye Res. 2008;87:35–48. · DOI
- Haider NB, Zhang W, Hurd R, Ikeda A, Nystuen AM, Naggert JK, et al. Mapping of genetic modifiers of Nr2e3 rd7/rd7 that suppress retinal degeneration and restore blue cone cells to normal quantity. Mamm Genome. 2008;19:145–54. · DOI · Paper page
Cited by
Inherited retinal diseases: Therapeutics, clinical trials and end points—A review
Georgiou, M., Fujinami, K., & Michaelides, M. (2021) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.13917 · Cited by 171
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Self-citationGeorgiou, M., Robson, A. G., Fujinami, K., de Guimarães, T. A. C., Fujinami‐Yokokawa, Y., Varela, M. D., Pontikos, N., Kalitzeos, A. A., Mahroo, O. A., Webster, A. R., et al. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101244 · Cited by 135
Gene-agnostic therapeutic approaches for inherited retinal degenerations
John, M. C., Quinn, J., Hu, M. L., Cehajic‐Kapetanovic, J., & Xue, K. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1068185 · Cited by 43
Targeting of the NRL Pathway as a Therapeutic Strategy to Treat Retinitis Pigmentosa
Moore, S. M., Skowronska‐Krawczyk, D., & Chao, D. L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072224 · Cited by 31
Metadata
- Authors
- Li, S., Datta, S., Brabbit, E., Love, Z., Woytowicz, V., Flattery, K., Capri, J., Yao, K., Wu, S., Imboden, M., Upadhyay, A., Arumugham, R., Thoreson, W. B., DeAngelis, M. M., & Haider, N. B.
- Affiliations
- Massachusetts Eye and Ear Infirmary (US)
- Ocugen, Inc. (United States) (US)
- University of Nebraska Medical Center (US)
- Corresponding author
- Haider, Neena B.
- Venue
- Gene Therapy
- Published
- 2020-03-02
- Volume
- 28
- Issue
- 5
- Pages
- 223-241
- ISSN
- 0969-7128 (ISSN-L)
- 1476-5462
- PMC
- PMC7483267
- OpenAlex
- W3009194131
- Cited by
- 68
- References
- 106
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 15 · 2023: 15 · 2022: 7 · 2021: 7 · 2020: 6
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-09-18)
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Gene Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DigitalCommons@UNMC (submittedVersion, cc-by)
- Funders
- American Macular Degeneration Foundation
- Research to Prevent Blindness
- Hope For Vision
- Massachusetts Lions Eye Research Fund
- U.S. Department of Health & Human Services | NIH | National Eye Institute (RO1EY017653, RO1EY017653-01A2S1)
- Ocugen INC
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- NR2E3, retinitis pigmentosa, retinal degeneration, nuclear receptors, photoreceptors, retinal homeostasis, transcription factors, genetic modifiers, mouse model, electroretinogram
- MeSH terms
- Animals, Disease Models, Animal, Homeostasis, Humans, Photoreceptor Cells, Retina, Retinal Degeneration, Retinitis Pigmentosa, Mice, Orphan Nuclear Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nr2e3 is a genetic modifier that rescues retinal degeneration and promotes homeostasis in multiple models of retinitis pigmentosa. https://app.cochat.ai/papers/10.1038/s41434-020-0134-z
- The paper
- Li, S., Datta, S., Brabbit, E., Love, Z., Woytowicz, V., Flattery, K., Capri, J., Yao, K., Wu, S., Imboden, M., Upadhyay, A., Arumugham, R., Thoreson, W. B., DeAngelis, M. M., & Haider, N. B. (2021). Nr2e3 is a genetic modifier that rescues retinal degeneration and promotes homeostasis in multiple models of retinitis pigmentosa. Gene Therapy. https://doi.org/10.1038/s41434-020-0134-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.